<DOC>
	<DOCNO>NCT00948727</DOCNO>
	<brief_summary>The purpose trial ass whether adaptation cyclosporine ( CsA ) dose accord longitudinal calcineurin ( CN ) activity monitoring would prevent onset graft-versus-host disease ( GVHD ) .</brief_summary>
	<brief_title>Cyclosporine Dose Adjustment According Calcineurin Activity After Allogeneic Hematopoietic Stem-cell Transplantation</brief_title>
	<detailed_description>Our previous study establish correlation increase calcineurin ( CN ) activity risk develop severe acute GVHD allogeneic stem cell transplant recipient receive immunosuppressive therapy calcineurin inhibitor . This proof-of-concept trial aim evaluate CALCIneurin activity monitoring biomarker efficacy cyCLOsporine - ( CALCICLO ) - prophylaxis acute GVHD . Our aim ass whether longitudinal monitoring CN activity would permit adapt optimize dose CsA would prevent onset severe acute GVHD , yet still maintain acceptable tolerability profile .</detailed_description>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>Patients age 12 60 year Patients plan receive allogeneic HSCT follow myeloablative condition regimen Transplant syngeneic donor Evidence refractory disease Nonmyeloablative conditioning Any participation study new investigational drug within previous 3 month</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>July 2009</verification_date>
</DOC>